SCHEMBL3283792

SCHEMBL3283792

CC(C)(C)OC(=O)C1NCCc2c(C(=O)O)cccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPKAPK2 P49137 5/20 0.37
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
RECQL P46063 1/20 0.33
IDO1 P14902 1/20 0.33
MAPKAPK5 Q8IW41 1/20 0.33
ALOX15 P16050 1/20 0.33
DRD2 P14416 2/20 0.32
DRD1 P21728 1/20 0.32
DRD4 P21917 1/20 0.32
DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29710295 0.87 RECQL (0.34) MEN1KMT2AATMDDB1CRBN
SCHEMBL27976569 0.82 TSHR (0.47) TSHRNPSR1MAPKAPK2MEN1KMT2A
SCHEMBL1967366 0.79 TSHR (0.41) TSHRNPSR1ALDH1A1HSD17B10DRD2
SCHEMBL7694988 0.78 TSHR (0.60) TSHRNPSR1MEN1KMT2AGID4
SCHEMBL30829405 0.78 TSHR (0.60) TSHRNPSR1MEN1KMT2AGID4
SCHEMBL30442509 0.78 TSHR (0.60) TSHRNPSR1MEN1KMT2AGID4
SCHEMBL17674692 0.76 TSHR (0.39) TSHRNPSR1MAPKAPK2ALDH1A1CYP1A2
SCHEMBL28094298 0.75 TSHR (0.41) TSHRNPSR1MEN1KMT2AALDH1A1
SCHEMBL27976229 0.73 TSHR (0.50) TSHRNPSR1MAPKAPK2MAPKAPK5DRD2
SCHEMBL28242066 0.73 GAA (0.37) ALDH1A1CYP1A2HPGDHSD17B10RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714018-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2010-05-11 US disclosed
EP-1761542-B1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2008-01-02 EP disclosed
US-20070117859-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-05-24 US disclosed
EP-1761542-A2 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP disclosed
US-7164019-B2 Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC ROCHE PALO ALTO LLC (US) 2007-01-16 US disclosed
US-20060014767-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-01-19 US disclosed
WO-2005121145-A2 OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014767-A1 Heterocyclic antiviral compounds CCR5, ACKR3, CXCR1 TSHR 1209/4885NPSR1 251/4885MAPKAPK2 1880/4885
US-20070117859-A1 Heterocyclic antiviral compounds CCR5, ACKR3, CXCR1 TSHR 1209/4885NPSR1 251/4885MAPKAPK2 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.